EN | TR
E-ISSN: 1308-6308 ISSN: 1304-9054
Evaluation of Vitamin B12 Levels in Pediatric Familial Mediterranean Fever Patients on Colchicine Treatment
PDF
Cite
Share
Request
Original Article
VOLUME: 16 ISSUE: 2
P: 86-92
August 2018

Evaluation of Vitamin B12 Levels in Pediatric Familial Mediterranean Fever Patients on Colchicine Treatment

J Curr Pediatr 2018;16(2):86-92
DOI: 10.4274/jcp.2018.0023
Özge Başaran
Nermin Uncu
1. Sağlık Bilimleri Üniversitesi Ankara Çocuk Sağlığı ve Hastalıkları Hematoloji Onkoloji Eğitim ve Araştırma Hastanesi, Çocuk Romatoloji Bölümü Ankara
No information available.
No information available
PDF
Cite
Share
Request

ABSTRACT

DISCUSSION and CONCLUSION:

According to our study results there is no need to evaluate serum vitamin B12 levels regularly in patients receiving colchicine treatment. On the other hand vitamin B12 levels may be decreased in patients on high dosage of colchicine.

RESULTS:

The mean vitamin B12 values were not significantly different between the patient and control groups (295.14 ± 171.62 pg/mL vs. 301.55 ± 148.86 pg/mL, p=0.66). Mean vitamin B12 level of the patients that were on colchicine therapy for more than 3 years (208.37±40.57 pg/ml) was not significantly different from the patients who were on colchicine therapy for less than 3 years (390.77±124.19) (p=0.0001, p<0.005). Median vitamin B12 levels were significantly lower in patients who received 1mg/day and higher colchicine therapy than the patients that received less than 1mg/day colchicine therapy (275 pg/ml vs. 197 pg/ml, p=0.04).

METHODS:

Ninety-eight pediatric FMF patients on at least one-year colchicine therapy and age and sex matched 49 healthy controls were enrolled. Complete blood count and vitamin B12 levels were measured. Patients were divided into two groups according to the duration (more than 3 years and less than 3 years) and dosage (more than 1mg/day and less than 1mg/day) of colchicine therapy.

INTRODUCTION:

Familial Mediterranean fever (FMF) is an auto inflammatory disease characterized by acute, short episodes of serosal membrane inflammation and fever. Regular prophylactic treatment with colchicine at a dose of 1 – 2 mg daily prevents or substantially reduces FMF attacks and complications. The aim of this study is to evaluate the serum vitamin B12 levels in pediatric FMF patients and also compare the duration and dosage of colchicine therapy and vitamin B12 levels.